|Tested species reactivity||Mouse|
|Published species reactivity||Not Applicable|
|Host / Isotype||Rat / IgG2a|
|Immunogen||Nonparenchymal cells from DDC-treated mice|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:50-1:100|
|Immunohistochemistry (Frozen) (IHC (F))||1:100|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
This antibody is specific for hepatic proliferating duct cells.
Facultative liver stem cell activation was originally described in the rat, where chemical damage and partial hepatectomy caused the emergence of a new cell type, the oval cell. These cells are thought to be bipotential progenitors capable of yielding both hepatocytes and bile ducts (1). To properly determine the molecular regulation of the progenitor process, appropriate markers are needed to identify and isolate cells that emerge during the oval cell response.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis.
MA5-16136 was used in immunohistochemistry - paraffin section to characterize attenuation of liver fibrosis by direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo
|Song G,Pacher M,Balakrishnan A,Yuan Q,Tsay HC,Yang D,Reetz J,Brandes S,Dai Z,Pützer BM,Araúzo-Bravo MJ,Steinemann D,Luedde T,Schwabe RF,Manns MP,Schöler HR,Schambach A,Cantz T,Ott M,Sharma AD||Cell stem cell (18:797)||2016|